Guntur team reports phage therapy success against drug-resistant infections

A medical team in Guntur reported success using bacteriophage therapy against a multidrug-resistant infection. The work was published in the International Journal of Infectious Diseases (IJID Regions) and supported by a biomedical research grant from the Sree Padmavathi Venkateswara Foundation. It matters because some patients do not improve with standard antibiotics.

The patient had a persistently discharging wound in his left knee. The infection was caused by multidrug-resistant Pseudomonas aeruginosa. Several antibiotic courses at different institutions had not produced complete recovery. After consulting Dr. Kalyan Chakravarthy Koganti and his team, he received phage therapy and recovered completely.

Dr. Kalyan reported that the patient had stayed infection-free and could walk for nine months. Dr. Sutharsan Govindarajan developed the required phages, while other specialists provided technical and clinical support. The team hopes this research will help more people with drug-resistant infections.

A bacteriophage, or phage, is a virus that infects bacteria rather than human cells. Each phage usually recognizes particular bacterial features, so it may attack one species or strain but leave many other microbes untouched. Phage therapy uses these bacteria-targeting viruses as a treatment for difficult infections. The approach matters because some bacteria resist multiple antibiotics.

After finding a suitable match, doctors can deliver phages to the infected area or through another medically appropriate route. The phage attaches to a bacterial cell, enters it, uses the cell to make more phages, and eventually breaks the cell open. The newly released phages can infect nearby susceptible bacteria.

The Guntur team used phage therapy for a knee wound caused by multidrug-resistant Pseudomonas aeruginosa. The patient recovered completely. Phage therapy remains specialized, and its success depends on finding effective phages and providing proper clinical care.

Multidrug-resistant infections occur worldwide and are considered a serious public-health challenge. They can develop in hospitals and communities, and they are especially dangerous for people with severe illness, wounds, devices, or weakened defenses. The article does not provide a global number of cases or deaths, so its Guntur report cannot measure the problem’s full size.

Pseudomonas aeruginosa is an important cause of wound, bloodstream, lung, and other infections. It can resist several antibiotic classes, leaving doctors with fewer reliable choices. A persistently discharging wound, like the patient’s knee wound in this report, may signal an infection that has not been controlled.

The Guntur patient had received multiple antibiotic courses at different institutions without complete recovery. Phage therapy then produced a complete recovery. This single case is encouraging, but it does not establish how often the approach works. Broader studies are needed to assess safety, effectiveness, and scale.

When a suitable bacteriophage encounters a bacterium, it attaches to the cell and injects its genetic material. The phage then redirects the bacterial cell to produce new phage particles. In the final stage of this infection cycle, the cell usually breaks open, releasing phages that can attack nearby susceptible bacteria.

This mechanism differs from antibiotic action. Antibiotics may block cell-wall construction, protein production, DNA processes, or other bacterial functions. Resistance can make those drugs ineffective. A properly matched phage may still recognize and destroy the bacterium because it uses a different biological route. Some phages also multiply where susceptible bacteria are present.

The Guntur team applied this principle to multidrug-resistant Pseudomonas aeruginosa in a persistent knee wound. The patient recovered completely after phage therapy. However, phages are not universally effective. Their activity must be tested against the patient’s bacterial strain, and treatment still requires medical supervision.

Therapeutic phages are usually developed by collecting phages from environmental or laboratory sources, growing them, and testing whether they infect the target bacterium. Researchers then identify useful phages, remove unwanted contaminants, and produce a preparation suitable for medical use. These laboratory steps vary by program and are not detailed in the article.

Matching is essential because phages often work only against particular bacterial species or strains. A laboratory can grow bacteria from the patient’s sample and expose them to candidate phages. Phages that reliably kill that isolate may be selected, sometimes as a combination. Doctors also consider the infection site, delivery method, and patient safety.

In Guntur, Dr. Sutharsan Govindarajan, an associate professor and phage biologist at SRM University-A.P., developed the required bacteriophages. The article does not describe the matching tests or preparation process. The patient’s complete recovery shows the treatment was successful in this reported case.

When phage therapy is unavailable, doctors first obtain cultures and antibiotic-susceptibility results whenever possible. They may then choose an active drug such as ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, or cefiderocol. Aminoglycosides or polymyxins may be considered in selected cases, but toxicity and resistance are important concerns. Drug choices depend on local guidance and testing.

Treatment also requires control of the infection’s source. Clinicians may drain an abscess, remove infected material, clean or debride a wound, or address an infected device when appropriate. Severe infections may require hospital care, intravenous treatment, and support for organ problems. These decisions must be made by infectious-disease and surgical teams.

The article reports only the successful phage approach, not alternative drugs used for this patient. For a multidrug-resistant Pseudomonas infection, phages should not replace careful culture testing, wound care, source control, or established antimicrobial treatment when an effective option exists.

Bacteria become antibiotic-resistant through genetic changes and by acquiring resistance genes from other bacteria. These changes can alter the drug’s target, destroy or modify the medicine, prevent the drug from entering, or pump it back out. Bacteria may also survive in protective communities called biofilms. Resistance can spread when antibiotics are overused, misused, or poorly completed, although resistance also arises naturally.

Multidrug resistance means that several antibiotic groups no longer work reliably. The Guntur patient had a persistent knee wound caused by multidrug-resistant Pseudomonas aeruginosa. Multiple antibiotic courses at different institutions had not achieved complete recovery. This illustrates how resistance can turn a treatable infection into a prolonged clinical problem.

New approaches are needed because resistance can narrow the available options. Phages offer a different way to target bacteria, but they require careful matching and clinical oversight. The Guntur team hopes its research will benefit more patients with drug-resistant infections.